期刊文献+

治疗丙肝药物研发进展综述 被引量:8

Progress in Drug Treatment of Hepatitis C
下载PDF
导出
摘要 本文主要对丙肝的药物治疗历史和新药研发进展进行了一个较为全面的总结和回顾,并重点介绍了2011年以来新上市的直接抗病毒丙肝药物的治疗效果和市场情况,通过跟踪这些新药研发进程,梳理丙肝领域新药的发展方向,希望能为丙肝领域的后续研发提供相关的参考和借鉴作用。 This article conducted a comprehensive review on the history and progress in Hepatitis C drug. And it mainly introduced the treatment effect and market situation of new direct antiviral agents listed since 2011. By tracking the drug research process and combing the develop direction of the Hepatitis C drug, we hope it can provide reference for subsequent research in the treatment of Hepatitis C.
作者 田月 赵志刚
出处 《药品评价》 CAS 2016年第2期44-46,共3页 Drug Evaluation
基金 "药物管理平台"子课题 国家科技部"脑血管病创新药物临床评价技术平台"重大专项基金 编号:2008ZX09312-00
关键词 丙肝 抗病毒药物 新药研发 Hepatitis C Antiviral Drugs New Drugdevelopment
  • 相关文献

参考文献12

  • 1Choo Q-L, Kuo G, Weiner AJ, et al.. Isolation of a cDNA clone derivedfrom a blood-borne non-A, non-B viral hepatitis genome[J]. Science, 1989,244: 359-362.
  • 2Lavanchy D. The global burden of hepatitis C[J]. Liver International, 2009,29: 74-81.
  • 3张福奎,贾继东.慢性丙型肝炎合并肝脂肪变的诊治[J].药品评价,2007,4(2):88-90. 被引量:3
  • 4Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosisin chronic hepatitis C virus infection[J]. Hepatology, 2001, 34: 809-816.
  • 5杨晓宇,王菊仙.抗丙型肝炎病毒新药及治疗方案研究进展[J].中国新药杂志,2014,23(22):2624-2630. 被引量:10
  • 6McHutchison JG, Lawitz EJ, Shiffmanm L, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection[J]. New England Journalof Medicine, 2009, 361: 580-593.
  • 7Kiser JJ, Flexner C. Direct-acting antiviral agents for hepatitis C virusinfection[J]. Annual review of pharmacology and toxicology, 2013, 53:427.
  • 8Tang H, Grise H. Cellular and molecular biology of HCV infection andhepatitis[J]. Clinical Science, 2009, 117: 49-65.
  • 9Zeuzem S, Andreone P, Pol S, et al. Telaprevir for Retreatment of HCVInfection[J]. New England Journal of Medicine, 2011, 364: 2417-2428.
  • 10田月,赵志刚.全球重要领域的新药研发与进展[J].药品评价,2015,12(18):6-11. 被引量:5

二级参考文献41

  • 1Castera L,Hezode C,Roudot-Thoraval F,et al.Effect ofantiviral treatment on evolution of liver steatosis in patientswith chronic hepatitis C:indirect evidence of a role ofhepatitis C virus genotype 3 in steatosis[].Gut.2004
  • 2Ohata K,Hamasaki K,Toriyama K,et al.Hepatic steatosisis a risk factor for hepatocellular carcinoma in patients withchronic hepatitis C virus infection[].Cancer.2003
  • 3Belfort R,Harrison SA,Brown K,et al.A placebo-con-trolled trial of pioglitazone in subjects with nonalcoholicsteatohepatitis[].The New England Journal of Medicine.2006
  • 4Charlton MR,Pockros PJ,Harrison SA.Impact of obesityon treatment of chronic hepatitis C[].Hepatology.2006
  • 5Giannattasio A,Spagnuolo MI,Sepe A,et al.Is HCV infec-tion associated with liver steatosis also in children[].Journal of Hepatology.2006
  • 6Westin J,Lagging M,Dhillon AP,et al.Impact of hepaticsteatosis on viral kinetics and treatment outcome during an-tiviral treatment of chronic HCV infection[].J Viral Hep-at.2007
  • 7Hickman IJ,Clouston AD,MacDonald GA,et al.Effect ofweight reduction on liver histology and biochemistry in pa-tients with chronic hepatitis C[].Gut.2002
  • 8Ramesh S,Sanyal AJ.Hepatitis C and nonalcoholic fattyliver disease[].Seminars in Liver Disease.2004
  • 9Sanyal AJ,Contos MJ,Sterling RK,et al.Nonalcoholic fattyliver disease in patients with hepatitis C is associated withfeatures of the metabolic syndrome[].The American journal of Gastroenterology.2003
  • 10Ortiz V,Berenguer M,Rayon JM,et al.Contribution of obe-sity to hepatitis C-related fibrosis progression[].The American journal of Gastroenterology.2002

共引文献15

同被引文献105

引证文献8

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部